Skip to main content
RCUS
NYSE Life Sciences

Arcus and Summit Team Up to Test Novel Kidney Cancer Combo, Data by Mid-2027

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$30.05
Mkt Cap
$3.769B
52W Low
$8.84
52W High
$31.735
52W Position info
240% above low
Off High info
5.3% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

RCUS has more than doubled off its 52-week low of $8.84.

Summary

Arcus and Summit are launching a clinical trial collaboration to combine Arcus's HIF-2α inhibitor casdatifan with Summit's PD-1/VEGF bispecific ivonescimab in clear cell renal cell carcinoma, including first-line metastatic disease. The study will add a new cohort to Arcus's ongoing ARC-20 platform trial, with Summit supplying ivonescimab and Arcus sponsoring and conducting the study; both companies share costs and retain rights to their own molecules. Initial data is expected by mid-2027. This follows Arcus's Q1 revenue decline and recent trial discontinuations, making pipeline advancement critical. The collaboration targets a large market—kidney cancer is a top-10 U.S. cancer with ~80,450 new cases expected in 2026—and a high unmet need in metastatic disease where five-year survival is only 19%. For Summit, it expands ivonescimab's reach into a new indication with a differentiated combination.

At the time of this announcement, RCUS was trading at $30.05 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $8.84 to $31.74. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

RCUS - Latest Insights

RCUS
Nov 04, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $19.31
Real-time Price: $17.43 info
Change: -$1.88 (-10%) info
Market Cap: $2.51B info
RCUS
Nov 04, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $19.31
Real-time Price: $17.43 info
Change: -$1.88 (-10%) info
Market Cap: $2.51B info
RCUS
Oct 21, 2026, 10:53 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $18.03
Real-time Price: $17.43 info
Change: -$0.600 (-3%) info
Market Cap: $2.51B info
RCUS
Oct 21, 2026, 4:30 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $18.75
Real-time Price: $17.43 info
Change: -$1.32 (-7%) info
Market Cap: $2.51B info
RCUS
Oct 21, 2026, 4:22 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $19.01
Real-time Price: $17.43 info
Change: -$1.58 (-8%) info
Market Cap: $2.51B info